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Diabetic cardiomyopathyDiabetic cardiomyopathy is a heartmuscle-speciﬁc disease that increases the risk of heart failure andmortality in
diabetic patients independent of vascular pathology.Mitochondria are cellular power plants that generate energy
for heart contraction and concurrently produce reactive oxygen species that, if unchecked, may damage the
mitochondria and the heart. Elimination of damaged mitochondria by autophagy known as mitophagy is an es-
sential process for maintaining normal cardiac function at baseline and in response to various stress and disease
conditions.Mitochondrial structural injury and functional impairment have been shown to contribute to diabetic
heart disease. Recent studies have demonstrated an inhibited autophagic ﬂux in the hearts of diabetic animals.
Surprisingly, the diminished autophagy appears to be an adaptive response that protects against cardiac injury
in type 1 diabetes. This raises several questions regarding the relationship between general autophagy and selec-
tivemitophagy in the diabetic heart. However, autophagymay play a different role in the hearts of type 2 diabetic
animals. In this review, we will summarize current knowledge in this ﬁeld and discuss the potential functional
roles of autophagy andmitophagy in the pathogenesis of diabetic cardiomyopathy. This article is part of a Special
Issue entitled: Autophagy and protein quality control in cardiometabolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Autophagy is an intracellular catabolic pathway in which long-lived
proteins and organelles are delivered to and degraded in the lysosomes.
Basal level autophagy plays a house-keeping role to maintain cellular
homeostasis. In response to starvation and various stresses, autophagy
is activated to degrade and recycle cellularmaterials for energy homeo-
stasis and cell survival. However, unchecked autophagy can result in cell
death. General macro-autophagy is believed to be a bulk non-selective
process that eliminates cellular components indiscriminately. However,questosome 1; HDAC6, histone
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ganelle is exclusively targeted and escorted into autophagosomes, the
double-membrane vesicles that engulf the destined cargo [1]. When
the selective cargo is mitochondria, it is termed mitophagy, meaning
the degradation of mitochondria through the autophagic process. How
exactly mitophagy achieves its selectivity and speciﬁcity is under in-
tense research. Several molecules have been identiﬁed to serve as adap-
tors or receptors thatmediatemitophagy such as sequestosome 1 (p62),
histone deacetylase 6 (HDAC6), BCL2/adenovirus E1B interacting protein
3 (BNIP3), BNIP3-like (BNIP3L or NIX) [2,3] and FUN14 domain contain-
ing 1 (FUNDC1) [4]. The general bulk autophagy and the selective
mitophagy can occur under the same conditions but they do not neces-
sarily change together in the same direction [5], suggesting distinct regu-
latory mechanisms for autophagy and mitophagy.
Two-thirds of diabetic patients die from heart disease or stroke,
which highlights the importance of understanding and treating cardio-
vascular complications of diabetes including diabetic cardiomyopathy.
Convincing evidence indicates that mitochondrial dysfunction and
increased generation of reactive oxygen species (ROS) are critical to di-
abetic heart damage [6–9]. However, several clinical trials have failed to
conﬁrm the ability of antioxidant therapies to reduce heart failure in di-
abetic patients [10–14]. This may reﬂect the fact that antioxidants can
only scavenge or antagonize existing ROS, but cannot curb continuous
ROS generation from aged or injured mitochondria, which are a major
source and target of intracellular ROS in diabetes [15–18]. Thus, a more
effective treatment strategy for reducing diabetic cardiac injury may
be to timely eliminate dysfunctional mitochondria thereby preventing
ROS generation. Presumably, this could be achieved by improving
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mechanism responsible for mitochondrial degradation.
Recent studies have demonstrated that autophagy is inhibited in the
hearts of type 1 diabetic mice [19–22] and several forms of metabolic
syndrome and type 2 diabetic animal models [23–26], suggesting that
the inhibition of autophagymay contribute to diabetic cardiomyopathy.
However, in the case of type 2 diabetes, studies have not produced
consistent results to support a general protective role of autophagy in
diabetic cardiac injury. More surprisingly, in type 1 diabetic mouse
models, the diminished autophagy appears to be an adaptive response
that limits diabetic cardiac injury. This effect may be related to an up-
regulation of a non-canonical alternative autophagy and a restoration
of the selective mitophagy. In this review, we will summarize the avail-
able evidence that links autophagy and mitophagy to diabetic cardiac
injury and discuss the potential functional roles of these two pathways
in the pathogenesis of diabetic cardiomyopathy. This review is not
intended to give an exhaustive description of the machinery, detection
methods and regulatory mechanisms of autophagy or mitophagy.
These topics have been covered by excellent review articles elsewhere
[27–32].
2. Autophagy and cardiac homeostasis
Autophagy is themajor cellular pathway for degrading and recycling
long-lived proteins and organelles. It begins with the formation of
double-membrane vesicles termed autophagosomes that sequester
targeted cell constituents and fuse with the lysosomes to form
autolysosomes (Fig. 1). The inner membrane and the contents of
the autolysosomes are degraded by the lysosomal enzymes and
recycled. More than 30 autophagy-related (Atg) genes encode proteins
essential for the generation and maturation of autophagosomes
and autolysosomes which are collectively called autophagic vacuoles
(AVs). Induction of autophagy is tightly controlled by many positive
and negative regulators. Forming a complex with several partners, in-
cludingBeclin 1/Atg6, Atg14L, UVRAG, Ambra1, vacuolar protein sorting
15 (VPS15), and Bif-1, the class III phosphatidylinositol 3-kinase (PI3K
or VPS34) is required for autophagy induction. When autophagy is
initiated, the microtubule-associated protein 1 light chain 3 (LC3-I/
Atg8) is conjugated to phosphatidylethanolamine (PE) by Atg7 and
Atg3 to form LC3-II. LC3-II is then incorporated into both the inner and
the outer membranes of the autophagosomes and remains membrane-
bound until after autolysosomes are formed. LC3-II on the inner mem-
brane is degraded by lysosomal proteases, while LC3-II on the outer
membrane is recycled back to the cytosolic pool of free LC3 [33]. TheFig. 1. Diabetes inhibits cardiac autophagy. Hyperglycemia (type 1 diabetes), hyperinsulinemia
the inactivation of ULK1, a kinase essential for autophagy initiation. Autophagy begins with the
cell constituents and fuse with the lysosomes to form autolysosomes where the cargos are degr
Beclin 1, LC3, and Atg12–Atg5–Atg16 complex.Atg12–Atg5–Atg16 complex is essential for the formation of LC3-II
and autophagosomes [31]. The mechanistic or mammalian target of
rapamycin complex 1 (mTORC1) pathway, activated by insulin, growth
factors andmanymetabolic signals, is well known to inhibit autophagy,
presumably through phosphorylating and inactivating autophagy-
related protein kinase 1 (Atg1), whose mammalian homolog is known
as Unc-51-like kinase 1 (ULK1) [34]. As an energy sensor, the AMP-
activated protein kinase (AMPK) stimulates autophagy through multi-
ple mechanisms. For example, AMPK competes with mTOR to phos-
phorylate and activate ULK1 [34]. It also phosphorylates tuberous
sclerosis complex 2 (TSC2) and regulatory associated protein of mTOR
(Raptor) leading to the inhibition of mTORC1 [35,36]. AMPK induces,
phosphorylates and activates the FoxO transcription factors that in
turn promote autophagy [37–39]. In addition, AMPK can phosphorylate
JNK1 [40] and Beclin 1 [41], respectively, resulting in the activation of
the Vps34 complex and the induction of autophagy.
Autophagy plays an important role in the maintenance of normal
heart function and morphology [42–45]. At baseline, autophagy func-
tions as a cytoplasmic quality control mechanism to remove protein
aggregates and damaged organelles. Thus, disruption of autophagy by
ablating Atg5 gene results in cardiac dysfunction in old mice [46] and
worsens pressure overload-induced cardiac remodeling and heart
failure [47]. Cardiac speciﬁc ablation of the Class III PI3K/vacuolar
protein sorting 34 (Vps34), a critical regulator of autophagy, reduces
autophagy leading to cardiac hypertrophy and dysfunction [48]. More-
over, autophagic activity declines with aging in rodents and humans,
which may contribute to the increased incidence of heart disease with
aging [49]. In response to starvation or ischemia, autophagy is activated
to allow recycling of metabolic substrates and maintenance of energy
generation for myocardial survival [50,51]. Consistently, enhanced
autophagy in chronically ischemic myocardium is associated with re-
duced myocardial apoptosis [52]. Ischemia preconditioning-induced
cardioprotection may be partially mediated by autophagy [53]. In addi-
tion, haploinsufﬁciency of the Beclin 1 gene (Beclin 1+/−) accelerates
heart failure in desmin-related cardiomyopathy [54] and abolishes
rapamycin-conferred cardioprotection against ischemic injury [24].
These observations demonstrate a protective role for autophagy under
these conditions. However, under other conditions, dysregulated au-
tophagy appears to be detrimental to the heart, probably due to exces-
sive non-discriminative self-digestion of essential cellular constituents
or enzyme leakage from lysosomes or autolysosomes. For instance,
diphtheria toxin and the anticancer drug doxorubicin each can induce
autophagy, which triggers heart failure rather than protects the heart
[55,56]. Also, Beclin 1+/− mice are protected from cardiac damage(type 2 diabetes) and other metabolic signals inhibit AMPK and activate mTOR leading to
formation of double-membrane vesicles termed autophagosomes that sequester targeted
aded. Many proteins participate in the formation of autophagosomes such as class III PI3K,
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signaling by ablating mTOR [58] or Raptor [59] gene renders mice sus-
ceptible to heart failure, which is associated with enhanced autophagy.
Cardiac speciﬁc deletion of the insulin receptor genes induces excessive
autophagy, leading to myocyte loss, heart failure, and premature death
[60]. Collectively, these contrasting results underscore the dichotomous
nature of autophagy that could be either protective or detrimental
depending on the speciﬁc context [50,61]. As a result, either activation
or inhibition of autophagy can be a viable therapeutic strategy in heart
failure of different origins.
3. Autophagy and mitochondrial dysfunction
Mitochondria are essential for energy production andmetabolism in
a cell. Ironically, mitochondria are also critically involved in cell death
pathways. Therefore, strict mitochondrial quality control mechanisms
exist in the cell to ensure thatmetabolic functions are efﬁciently execut-
ed and cell death is appropriately orchestratedwhenneeded.Mitochon-
drial quality control can be performed at multiple points during the
mitochondrial life cycle, ranging from biogenesis, ATP production, pro-
tein folding, fusion and ﬁssion, motility, and degradation.Mitochondrial
degradation through autophagy is the important ﬁnal quality control
mechanism for maintaining a healthy and functional mitochondrial
network. Altered autophagy is closely associated with mitochondrial
dysfunction, suggesting a potential causative relationship between
the two. Indeed, autophagic activity declines with aging in rodents
and humans [49], which is accompanied by increased mitochondria in-
jury and enhancedROS generation [62,63]. Mice deﬁcient in Atg5 devel-
oped cardiac hypertrophy with impaired left ventricular function at
10 months of age [46] and had worse cardiac remodeling and heart
failure in response to pressure overload [47]. The cardiac dysfunction
was associated with increased aggregation of abnormal proteins and
enlarged or collapsed mitochondria that had diminished mitochondrial
respiratory functions. Conversely, caloric restriction is sufﬁcient to
accelerate cardiac autophagic ﬂux [64,65] and simultaneously reduce
mitochondrial oxidative damage in the heart [49,65–67]. These results
suggest that autophagy plays a very important role in maintaining
normal mitochondrial structure and function in the heart.
4. Mitophagy, a selective form of autophagy
Autophagy is a survival pathway that allows the cell to maintain
energy homeostasis in response to starvation or nutrient deprivation.
Conversely, autophagy can also trigger cell death upon stimulation by
various harmful stresses. Under both scenarios, the induced autophagy
has long been thought to be a non-selective bulk degradation pathway
that indiscriminately eliminates cellular components including mito-
chondria. However, autophagy can becomehighly selectivewhen a spe-
ciﬁc organelle is exclusively targeted and escorted into autophagosomes
which then transport the cargo to the lysosomes for degradation [14].
When the destined cargo is mitochondria, it is termed mitophagy,
meaning the degradation of mitochondria through the autophagic pro-
cess. Although activation of general autophagy may be accompanied by
increased mitophagy under certain conditions, it is now very clear that
the functional status of general bulk autophagy may not necessarily
reﬂect the activity of the selective mitophagy. For example, mitophagy
can be induced under nutrient-rich conditions to remove superﬂuous
or injured mitochondria when general autophagy is not activated or
even inhibited [28]. Conversely, starvation activates autophagy in sever-
al cell types, including muscle cells. However, mitochondrial degrada-
tion is not increased correspondingly. Instead, mitophagy is inhibited
during starvation, which is accompanied by increased mitochondrial
elongation [5]. Similarly, cyclosporin A can induce general autophagy
in rat kidney cells [68] and in mouse muscle cells [69], but it attenuates
mitophagy in human ﬁbroblasts. Collectively, these observations sug-
gest that general autophagy and selective mitophagy can change inopposite directions and they are regulated by different signaling path-
ways [70,71]. How exactly mitophagy achieves its selectivity and spec-
iﬁcity is under intense research. Several mechanisms have been
identiﬁed that confer the selective nature of mitophagy.
Mitophagy is closely associatedwithmitochondrialﬁssion, a process
that splits largemitochondria into smaller daughter mitochondria. Con-
trolled mainly by dynamin-related protein 1 (Drp1), mitochondrial ﬁs-
sion events segregate damaged segments of mitochondria and facilitate
their removal by mitophagy [72]. Inhibition of ﬁssion by inactivating
Drp1 prevents mitophagy, suggesting that ﬁssion may be required for
mitophagy [28]. Several pathways have been shown to regulate the
initiation of mitophagy (Fig. 2). A common trigger for mitophagy is
the mitochondrial depolarization induced by various stimuli. When
dysfunctional mitochondria lose their membrane potential ΔΨm, the
serine/threonine protein kinase PINK1 (phosphatase and tensin homo-
log-induced putative kinase 1) becomes activated and stabilized on the
mitochondrial outer membrane [73]. The activated PINK1 then phos-
phorylates speciﬁc proteins including mitofusin 2 (Mfn2) that serves
as a receptor to recruit Parkin [74], an E3 ubiquitin (Ub) ligase that
normally resides in the cytosol. Upon translocation to depolarizedmito-
chondria, Parkin is phosphorylated at serine 65 by PINK1 and becomes
activated [75]. Interestingly, the full activation of Parkin requires
PINK1 to phosphorylate ubiquitin at serine 65 aswell [76]. The activated
Parkin then ubiquitinates mitochondrial proteins including voltage-
dependent anion channel 1 (VDAC1), Mfn1 and Mfn2 [77–84]. These
ubiquitinated mitochondria bind p62 and HDAC6 through the ubiquitin-
binding domain and are transported along microtubules to cluster in
the perinuclear region [85,86]. P62 then recruits autophagosomal mem-
branes via LC3 through its LC3-interacting domain, leading to mitochon-
drial clearance in the lysosome [86,87]. Another E3 ligase SMAD-speciﬁc
E3 ubiquitin protein ligase 1 (SMURF1) is downstream of Parkin and
promotes mitophagy independently of its catalytic activity [88]. In addi-
tion, NIX or BNIP3 and FUNDC1 may serve as mitophagy receptors that
bridge mitochondria and LC3 to selectively induce mitochondrial degra-
dation [2–4]. NIX or Bnip3 is inserted into the outer mitochondrial mem-
brane through its C-terminal transmembrane domains, and recruits
autophagy machinery by directly binding to LC3/GABARAP proteins on
the autophagosome via the N-terminal LC3-interacting motifs [89,90].
Also, NIX and BNIP3 may directly trigger mitochondrial depolarization,
which by itself has been shown to be sufﬁcient to induce mitophagy
[72,91]. Thus far, it remains controversialwhether andhowNIX/BNIP3 in-
teracts with Parkin to regulate mitophagy. Of note, both NIX and BNIP3
can induce cell death, but it is currently unclear how the pro-death and
pro-mitophagy functions of NIX or BNIP3 are coordinated or differentially
regulated under normal or disease conditions [3]. Another mitophagy re-
ceptor is FUNDC1, a mitochondrial outer-membrane protein that recruits
the autophagosome through its typical LC3-binding motif similar to NIX/
BNIP3. FUNDC1-mediated mitophagy is inhibited by its phosphorylation
at tyrosine 18 in the LC3 interactingmotif by Src kinase [4], but enhanced
by its phosphorylation at serine 17 by ULK1 [92]. FUNDC1-induced
mitophagy is Atg5 dependent but Beclin 1 independent. It does not
seem to require Parkin since FUNDC1was sufﬁcient to inducemitophagy
in HeLa cells that do not express Parkin. Unlike NIX or BNIP3, FUNDC1
does not induce cell death, suggesting a unique functional role for
FUNDC1 in mitochondrial quality control that may be harnessed for
therapeutic purposes [4].
Mitophagy is a process in which dysfunctional or otherwise
depolarized mitochondria are selectively sequestered by autophagic vac-
uoles and subsequently degraded within the lysosomes (Fig. 2). As such,
the occurrence ofmitophagy can be determined by the colocalization of a
mitochondrial protein with a lysosomal or autophagosomal protein.
However, this approach suffers from low resolution and low speciﬁcity.
Transmission electron microscopy can provide direct evidence for
mitophagy but it is hard to quantify. A novel Rosella mitophagy reporter
has been described in Yeast that allows direct visualization and quantiﬁ-
cation of the mitochondria that are degraded through the mitophagic
Fig. 2. An illustration of the mitophagic pathways. Damaged and depolarized mitochondrial segments are segregated through Drp1-mediated ﬁssion. PINK1 is activated uponmitochon-
drial depolarization and promotes Parkin translocation from the cytosol to the damaged mitochondria. Parkin ubiquitinates mitochondrial proteins that bind adaptor proteins p62 and
HDAC6. The latter two recruit autophagosomal membranes through LC3 triggering mitochondrial clearance. Alternatively, Nix or BNIP3 and FUNDC1 may serve as receptors that bridge
mitochondria and LC3 to induce mitophagy independently of Parkin.
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comprising a pH-stable red ﬂuorescent protein (RFP) linked to a pH-
sensitive green ﬂuorescent protein (GFP). Mitochondria that appear
green or yellowonmergedﬂuorescent images are located in the cytosolic
compartments, while those who give rise to only red ﬂuorescence are
being degraded within the autolysosomes where the pH is low and the
GFP is quenched. A similar reportermCherry-GFP-FIS1was used to quan-
tify mitophagy in U2OS cells and SH-SY5Y cells [94]. In addition, Keima, a
coral-derived acid-stable ﬂuorescent protein, has been used to monitor
mitophagy in mouse embryonic ﬁbroblast cells [95]. Keima emits a red
ﬂuorescent signal at acidic pH (586 nm) and a green ﬂuorescent signal
at higher pH (438 nm). Similar to Rosella and mCherry-GFP-FIS1,
Keima-labeled mitochondria that appear red are being degraded within
the autolysosomes. It would greatly facilitate mitophagy research at the
whole animal level if Rosella, mCherry-GFP-FIS1 or Keima mitophagy
reporter mice can be constructed.
5. Mitophagy and cardiac homeostasis
Given its importance in maintaining a healthy mitochondrial net-
work, mitophagy has been shown, not surprisingly, to be essential
for myocardial protection under both physiological and pathological
conditions [96–103]. For instance, overexpression of Parkin is sufﬁcient
to inducemitophagywhenmitochondria lose theirmembrane potential
[104] and to prevent cardiac dysfunction in agedmice [100]. Conversely,
inhibition of mitophagy respectively by Parkin deﬁciency [101],
SMURF1-deﬁciency [88] or BNIP3 and NIX deﬁciency [105] leads to an
accumulation of abnormal mitochondria in cardiomyocytes. Parkin ab-
lation abolishes the cardioprotective effect of ischemic preconditioning
[96] and results in more severe cardiac injury following myocardial
infarction [97]. Together, these results demonstrate an indispensable
role for mitophagy in maintaining cardiac homeostasis under severalconditions. However, it is currently unknown whether excessive
mitophagy can cause heart damage in any cardiac or systemic patholo-
gies, despite the fact that ischemia–reperfusion and the deletion of
both Mfn 1 and Mfn 2 induce excessive mitochondrial fragmentation
and cardiac damage, which may suggest a potential involvement of
mitophagy [106,107].
6. Canonical, non-canonical autophagy and mitophagy
Canonical autophagy begins with the formation of the
autophagosome, the vesicle that engulfs cellular components and de-
livers them to the lysosome for degradation. A set of autophagy-
related proteins including Atg5 and Atg7 is required for the generation
of the autophagosome. However, recent studies have demonstrated
the existence of non-canonical forms of autophagy. Dr. Shimizu's
group described an Atg5- and Atg7-independent pathway that controls
autophagy through the unconventional biogenesis of canonical
autophagosomes. This alternative autophagy was regulated by ULK1
and Beclin 1. The formation of the autophagosome depends on the
small GTPase Rab9, but not Atg5, which facilitates the fusion of isolation
membrane or phagophore with vesicles derived from the trans-Golgi
and late endosomes. Interestingly, the Rab9 dependent alternative
autophagic pathway is responsible for mitochondrial degradation
during erythrocyte differentiation [108], raising the possibility that
the Rab9-dependent non-canonical autophagy may also contribute to
mitophagy in the heart under certain conditions.
7. Diabetic heart disease is amajor causeof death indiabetic patients
Diabetes is a risk factor for the development of various cardiovascu-
lar complications, which constitute the leading causes of death in both
type 1 and type 2 diabetic populations. The susceptibility of diabetic
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factors such as obesity, hypercholesterolemia, atherosclerosis and hy-
pertension. However, a heart muscle-speciﬁc disease independent of
vascular pathology, namely diabetic cardiomyopathy, has been recog-
nized as an important causative factor for the heightened risk of heart
failure and mortality in diabetic patients [6,7].
8. Diabetic cardiomyopathy is closely related to mitochondrial
dysfunction and ROS generation
In diabetes, mitochondria are a predominant source of intracellular
reactive oxygen species (ROS) and are themselves a primary target of
oxidative injury [17,18]. Damaged mitochondria can further increase
ROS production through ROS-induced ROS release [109,110] and may
trigger leakage of pro-death factors, setting in motion a vicious cycle
to induce cardiomyocyte death [111–115]. Indeed, increasedmitochon-
drial production of ROS and damagedmitochondrial structure and func-
tion are commonly seen in the hearts of both type 1 and type 2 diabetic
patients and animal models [15,16,115–118]. The causative role of ROS
in the pathogenesis of diabetic cardiomyopathy is well established in
animal studies by the ability of various antioxidants to reduce diabetic
heart injury [9,114,119–122]. However, the efﬁcacy of antioxidant ther-
apy has not been reproduced in diabetic patients thus far [10–14]. The
inconsistency between animal studies and clinical trials could result
from the heterogeneity of the patient populations and/or the types of
antioxidants used. Further research in more homogeneous patients
using more robust antioxidants may help resolve this issue. On the
other hand, it is possible that antioxidants cannot block continuous for-
mation of ROS despite their ability to scavenge existing ROS. If this is
true, a more effective therapeutic strategy for diabetic cardiomyopathy
may be to timely eliminate aged and dysfunctional mitochondria which
would otherwise constantly generate ROS and release pro-death factors.
Presumably, this could be achieved by autophagic sequestration and
lysosomal degradation of injured mitochondria, a process termed
mitophagy that plays an important role inmitochondrial quality control
and cellular homeostasis.
9. Autophagy is inhibited in the diabetic hearts
Insulin signaling activates the PI3K–Akt/PKB–mTORC1 pathway not
only to stimulate protein synthesis, but also to concurrently inhibit au-
tophagy [123,124]. It was thus hypothesized that insulin deﬁciency
(type 1 diabetes) or insulin resistance (type 2 diabetes) would increase
autophagic activity [125]. Consistently, mice deﬁcient in insulin recep-
tor substrates have increased cardiac autophagy [60]. However, diabe-
tes caused by either insulin deﬁciency or insulin resistance is often
accompanied by varying degrees of hyperglycemia, hyperinsulinemia,
dyslipidemia and other signaling changes that can also affect the au-
tophagic activity. For example, high levels of glucose can directly inhibit
autophagy in cardiomyocytes [126]. Increased palmitic acid can sup-
press autophagy in hepatocytes [127] but induce autophagy in H9c2
cardiac myoblasts [128]. Accordingly, the ultimate functional status of
autophagy in the diabetic heart will reﬂect a net effect of insulin deﬁ-
ciency or resistance, hyperglycemia and/or other changes associated
with diabetes. Indeed, despite insulin deﬁciency, autophagy is reduced
rather than increased in the hearts of OVE26 [19] and streptozotocin
(STZ)-induced type 1 diabetic mice [19–21]. Speciﬁcally, diabetes re-
duced the protein levels of LC3-II, a lipidated formof LC3 that is incorpo-
rated into the membrane of an autophagic vacuole (AV). The LC3-II
levels are a function of both the formation and degradation of the AVs
and are proportional to the number of AVs at the time LC3-II is mea-
sured [129]. The inhibition of autophagy in both OVE26 and STZ type
1 diabetic hearts was conﬁrmed by the reduced autophagic ﬂux as
determined by the difference in LC3-II levels and the GFP-LC3 puncta
in the absence and presence of Baﬁlomycin A1, a lysosomal inhibitor
that blocks autophagic degradation [22]. The fact that the mTORC1signaling pathway is activatedwhile the AMPK is inhibited in the hearts
of type 1 diabetic mice [19–22] provides a mechanistic explanation for
the inhibited autophagy (Fig. 1).
Cardiac autophagy in type 2 diabetes is reported to be inhibited in a
number of studies but it is not as consistent as in type 1 diabetes. For
example, cardiac autophagywas inhibited in obesity andmetabolic syn-
drome induced by high fat diet [23–26], but it was activated by fructose-
induced insulin resistance and hyperglycemia [130]. Moreover, a milk
fat-based diet was reported to activate autophagy and induce cardiac
hypertrophy in mice [131]. Another study reported unchanged cardiac
autophagy inmice fed a high fat diet [132]. The different cardiac autoph-
agic responses to diet-induced metabolic changes can be partially ex-
plained by the variation in duration of the dietary intervention and
the types and relative contents of carbohydrates and lipids in the diets
[133]. Of note, not all studies have determined the autophagic ﬂux in
the heart, which may contribute to the variation among different
reports. Autophagic ﬂux reﬂects the number of autophagic vacuoles
(AVs) that are delivered to anddegraded in the lysosome; it can bemea-
sured by the difference in the protein levels of the LC3-II or the numbers
of AVs in the absence and presence of a lysosomal inhibitor such as chlo-
roquine [134,135] and Baﬁlomycin A1 [22,136]. The importance of using
autophagic ﬂux instead of static levels of LC3-II as a marker for autoph-
agic activity was elegantly demonstrated in a recent study that investi-
gated the protective effects of Akt2 deletion against high fat diet (HFD)-
induced cardiac dysfunction [26]. Although cardiac LC3-II levels in wild
type mice were increased by HFD, they were not an indication of
increased autophagic activity. Instead, the accumulated LC3-II was due
to an impaired clearance of AVs, as chloroquine did not further elevate
cardiac LC3-II levels, suggesting an inhibited autophagic ﬂux in mice
fed HFD. However, Akt2 knockout relieved the inhibition and main-
tained a very high level of autophagic ﬂux as indicated by dramatically
increased LC3-II levels by chloroquine [75]. Another useful marker for
autophagic activity is p62, a polyubiquitin-binding protein that is
degraded by autophagy and its protein levels are inversely related to au-
tophagic activity [47,137,138]. Indeed,HFD inhibited cardiac autophagic
ﬂux in mice, which was accompanied by increased p62 protein levels
[24–26]. Nevertheless, cardiac p62 levels were increased also in
fructose-induced insulin resistance, which was not readily explainable
by enhanced autophagy [130]. Measuring autophagic ﬂux may help re-
solve this issue. Interestingly, themTORC1 signaling pathway is activat-
ed, while the AMPK is inhibited, in the models that do show inhibited
cardiac autophagy [24–26], consistent with ﬁndings in type 1 diabetic
hearts [19,22]. Conversely, fructose-induced cardiac autophagy is asso-
ciated with reduced phosphorylation of Akt and the mTORC1 down-
stream target ribosomal protein S6 [130]. Since mTORC1 negatively,
while AMPK positively, regulates autophagy, the functional status of
cardiac autophagy in diet-induced diabetes may be predicted by the
activities of mTORC1 and/or AMPK in the heart (Fig. 1).
10. The functional role of autophagy in the diabetic hearts
Previous studies not only have demonstrated an association be-
tween altered autophagy and diabetic cardiac injury but also have
attempted to address whether the altered autophagy contributes to
cardiac injury or promotes myocardial survival. Treatment of OVE26
and STZ diabetic mice with the anti-diabetic drug metformin reduced
cardiac injury [19,40]. Similarly, overexpression of heme oxygenase-1
(HO-1) [21] or mitochondrial aldehyde dehydrogenase (ALDH2, this
issue: Molecular Basis of Disease Special Issue on: Autophagy & protein
quality control) provided cardioprotection in STZ diabetic mice. Metfor-
min, HO-1 and ALDH2 each reversed the inhibited AMPK signaling and
autophagy in the diabetic heart. Since AMPK is a critical positive regula-
tor of autophagy, it was suggested that metformin, HO-1 or ALDH2 im-
proved cardiac function in type 1 diabetes through AMPK-mediated
upregulation of autophagy. The functional role of autophagywas direct-
ly tested in another study using both gain- and loss-of-function mouse
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attenuated in Beclin 1 deﬁcient (Beclin 1+/−) mice and exacerbated
by Beclin 1 overexpression [22], suggesting a detrimental role for au-
tophagy in the type 1 diabetic heart. Of note, a recent study questioned
the role of Beclin 1 as a positive regulator of autophagy. Speciﬁcally, Dr.
Diwan's group made an interesting observation that knockdown of
Beclin 1 enhanced the clearance of AVs in cultured cardiomyocytes,
suggesting that Beclin 1 deﬁciency may accelerate rather than reduce
autophagic ﬂux [91]. However, this possibility was not supported by
the fact that diabetes resulted in a greater inhibition of autophagic
ﬂux in Beclin 1+/− hearts and did not reduce autophagic ﬂux in Beclin
1 transgenic hearts as comparedwithwild type controls [22]. Moreover,
diabetic cardiac injury was also reduced in mice deﬁcient in Atg16, a
component of the Atg12–Atg5–Atg16 protein complex essential for
autophagosome formation [22]. This result further supported the
conclusion that the diminished autophagy is an adaptive response
that limits cardiac injury in type 1 diabetes. The results also sug-
gested that the cardioprotective effects of metformin, HO-1 or
ALDH2 on the diabetic heart may not necessarily be mediated by
autophagy. Instead, metformin, HO-1 or ALDH2 may protect the dia-
betic heart through other AMPK-induced signaling and metabolic
changes. For example, AMPK inhibits cellular processes that con-
sume ATP and activates ATP-generating pathways. It enhances mito-
chondrial oxidation of fatty acids [139] and promotes mitochondrial
biogenesis [140]. These autophagy-independent effects of AMPK
may account for the ability of metformin, HO-1 or ALDH2 to protect
the diabetic heart. It is also possible that metformin, HO-1 or ALDH2
may use AMPK-independent mechanisms to confer cardioprotection
in diabetes [141]. This hypothesis is supported by a recent study show-
ing that metformin can still robustly protect against pressure overload-
induced pathological cardiac remodeling in mice deﬁcient in AMPK
signaling [142]. Apparently, the exact molecular mechanism by which
metformin, HO-1 or ALDH2 protects the type 1 diabetic heart remains
to be elucidated.
In contrast to its adaptive nature in type 1 diabetes, the inhibited
cardiac autophagy inmost HFD-induced type 2 diabetic models appears
to be maladaptive, and thus strategies to enhancing autophagy may be
cardioprotective. For example, either cardiac speciﬁc haploinsufﬁciency
of mTOR (mTOR+/−) or rapamycin treatment was able to restore cardi-
ac autophagy in mice fed a HFD [24] and concurrently abolish the exag-
geration of myocardial infarction triggered by a 3-hour coronary artery
ligation. Rapamycin was unable to reduce the infarct size in HFD-fed
Beclin-1+/−micewhere autophagy could not be restored by rapamycin.
Also, Akt2 gene ablation inhibited mTORC1 activation and enhanced
cardiac autophagic ﬂux in mice fed a HFD, which was accompanied by
reduced cardiac hypertrophy and improved heart function [26]. Fur-
thermore, adiponectin deﬁciency augmented HFD-induced accumula-
tion of p62 and exacerbated HFD-induced cardiac remodeling and
dysfunction. These detrimental effects were abolished by rapamycin
treatment [25]. Collectively, these results suggested that autophagy re-
activation is responsible for the beneﬁcial effects of mTORC1 inhibition
in HFD-fed mice. Rapamycin was also shown to improve cardiac func-
tion in genetic type 2 diabetic mice deﬁcient in leptin receptor (db/db)
although the protective effects may not involve autophagy [143]. How-
ever, some studies reported activated cardiac autophagy in diet-induced
diabetes and suggested a harmful role for autophagy under these condi-
tions. For instance, the fructose-induced type 2 diabetes was associated
with suppressed survival signaling and increased cardiac pathology [71].
A milk fat-based diet led to adverse cardiac remodeling in mice [131].
These two studies proposed that the enhanced autophagy contributed
to cardiac injury in diet-induced diabetes, but this hypothesis remains
to be directly tested by using an autophagy deﬁcientmousemodel. Nev-
ertheless, by using the autophagy inhibitor 3-methyladenine, increased
autophagy was shown to exacerbate ischemic brain injury in a type 2
diabetic mouse model generated by combined administration of STZ
and nicotinamide [144].It is not readily explained why inhibition of cardiac autophagy
appears adaptive in type 1 diabetic models but maladaptive in most
HFD-induced type 2 diabetes. This may be related to the difference in
etiologies and coexisting conditions between type 1 and type 2 diabetes.
For example, HFD-induced diabetes, but not STZ or OVE26 diabetes, is
accompanied by overt obesity and metabolic syndrome that may
contribute to the different natures of the suppressed autophagy in the
hearts of type 1 and type 2 diabetic mice. On the other hand, the role
of cardiac autophagy in HFD-induced type 2 diabetic mice was tested
mostly by using rapamycin or mTOR+/− mice [24,25]. It is possible
that the beneﬁcial effects of rapamycin or mTOR deﬁciency on type 2
diabetic hearts may not be mediated exclusively through autophagy
restoration given that rapamycin or mTOR deﬁciency can activate
other signaling pathways such as Akt [58,145,146] that may contribute
to cardioprotection. Also, the increased mTOR activity in the hearts of
both type 1 and type 2 diabetic mice may be an adaptive response
since overexpression of mTOR was shown to protect from cardiac
dysfunction in pathological hypertrophy [147]. It will be of interest to
investigate if autophagy is inhibited in the mTOR transgenic hearts
and if and how diabetic injurywill be affected bymTOR overexpression.
Should mTOR overexpression turn out to inhibit autophagy and reduce
cardiac injury in HFD-induced diabetes, it would suggest that the
inhibited autophagy may also be an adaptive response in type 2 diabe-
tes and that the beneﬁcial effects of rapamycin or mTOR deﬁciency on
type 2 diabetic hearts aremediated throughmechanisms other than au-
tophagy restoration. Apparently, further research is required to resolve
this issue.11. Mitophagy and non-canonical autophagy in the diabetic heart
The functional status of general autophagy may not necessarily
reﬂect the activity of the selective mitophagy. Indeed, autophagy is
inhibited in the diabetic heart as early as 3 weeks after STZ injection,
but mitophagy is not reduced until advanced stages. More intriguingly,
mice deﬁcient in Beclin 1 or Atg16 had partially restored mitophagy
under overt diabetic conditions [22] as assessed by the expression
and mitochondrial localization of PINK1, Parkin, and the lysosomal-
associated membrane protein 1 (LAMP1). These results suggest that
the restoredmitophagymay have accounted for the attenuated diabetic
cardiac injury in autophagy-deﬁcient mice, which is supported by the
protective role of Parkin-mediated mitophagy in pancreatic β-cell
function in diabetes [148]. It is also very clear that mitophagy must be
mechanistically separable from general bulk autophagy to ensure the
selective nature of mitophagy that eliminates only dysfunctional mito-
chondria under diabetic conditions. Nevertheless, the functional role
of mitophagy and the speciﬁc regulatory mechanisms of mitophagy in
the diabetic heart remain to be determined. Interestingly, the reduced
cardiac autophagy in type 1 diabetes was associated with increased
expression of Rab9 [22], a small GTP binding protein implicated in a
non-canonical alternative autophagy that requires Rab9 and is responsi-
ble for mitochondrial degradation during erythrocyte maturation in the
absence of Atg5 [108]. Indeed, the increase in Rab9 protein levels was
more pronounced in the mitochondrial fraction, suggesting that Rab9
may be translocated to mitochondria to mediate their degradation in
the diabetic heart. Consistently, there is increased colocalization of
Rab9 with lysosomes in the diabetic Beclin 1+/− hearts [22]. It is thus
possible that when canonical autophagy is inhibited, alternative
autophagy is up-regulated, which may trigger mitophagy to protect
the diabetic heart (Fig. 3). This attractive hypothesis remains to be
directly tested by using Rab9 overexpressing and deﬁcient mice, or
more speciﬁcally, by disrupting themitochondrial or lysosomal localiza-
tion of Rab9. Additionally, the role of other non-canonical autophagic
pathways in the diabetic heart remains to be explored such as Beclin
1-independent but Atg7 dependent autophagy as described previously
in cancer cells [149]. It is expected that the next few years will see an
Fig. 3. The inhibited autophagy is cardioprotective in type 1 diabetes, which may be
explained by the increased Rab9-related alternative autophagy and restored mitophagy.
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that regulate these different autophagic or mitophagic pathways.
12. Conclusions and open questions
Autophagy is inhibited in the diabetic hearts. Whereas the dimin-
ished autophagy appears to contribute to cardiac injury in several type
2 diabetic animal models, it turns out to be cardioprotective in type 1
diabetes, which is linked to non-canonical alternative autophagy and
mitophagy (Fig. 3). There are many open questions that remain to be
addressed. For example, the functional role of mitophagy or Rab9-
dependent alternative autophagy has not been directly tested in the di-
abetic hearts by using either gain- or loss-of-functional models. It is also
not clear whether mitophagy uses the core machinery of autophagy or
alternative autophagy to perform its function. Given that mitochondria
may provide a membrane source for the autophagosome [150], how
does the cell determine whether just to contribute some of the mito-
chondrial membrane to autophagosomal formation or to induce
mitophagy altogether? For the same reason, is it possible that mito-
chondrial membrane can directly fuse with the lysosomes to form
mitolysosomes thus triggering mitophagy without the involvement
of autophagosomes? How are general autophagy and selective
mitophagy differentially regulated? Is it the same mitophagic path-
way that mediates the constitutive turnover of mitochondria at base-
line and the clearance of injured mitochondria in diabetes? How can
mitophagy be speciﬁcally upregulated without affecting general
autophagy? Under what conditions, if any, does mitophagy become
detrimental and contribute to cell death? Answers to these questions
will help elucidate the molecular mechanisms that regulate and
coordinate these different autophagic pathways so that their thera-
peutic potential could be harnessed for the treatment of diabetic
cardiomyopathy and heart failure.
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